Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents

Ian Neil Fleming, Morag Hogben, Sheelagh Frame, Steven J McClue, Simon R Green

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The aims of this study were to investigate whether the cyclin-dependent kinase inhibitor seliciclib could synergize with agents that target ErbB receptors and to elucidate the molecular mechanism of the observed synergy.
Original languageEnglish
Pages (from-to)4326-4335
Number of pages10
JournalClinical Cancer Research
Volume14
Issue number13
DOIs
Publication statusPublished - 2008

Keywords

  • Animals
  • Antineoplastic Agents
  • Cell Line, Tumor
  • Cyclin D1
  • Drug Synergism
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • Models, Biological
  • Mutation
  • Neoplasm Transplantation
  • Purines
  • Receptor, erbB-2

Fingerprint Dive into the research topics of 'Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents'. Together they form a unique fingerprint.

  • Cite this